Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Abby Beedy

Physician Assistant, Medical Maryville, IL Physician Assistant

NPI 1942497037 CMS profile 11121847

20 Professional Park Dr Ste B, Maryville, IL 62062

Open in the dashboard

General payments

$7,937

434 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Abby Beedy of Maryville, IL is reported in the CMS Open Payments database as having received $7,937 across 434 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,725 91
2024 General $1,607 84
2023 General $1,397 73
2022 General $1,360 72
2021 General $1,848 114

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Abby Beedy
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Abby Beedy were reported at $1,725. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Abby Beedy Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,848 $156 $41–$563 $132
2022 $1,360 $185 $55–$649 $149
2023 $1,397 $199 $58–$717 $160
2024 $1,607 $206 $62–$740 $164
2025 $1,725 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $1,854 64 payments
  2. AbbVie, Inc. $1,601 100 payments
  3. Lilly USA, LLC $1,191 77 payments
  4. Novo Nordisk Inc $409 28 payments
  5. GlaxoSmithKline, LLC. $346 23 payments
  6. OptiNose US, Inc. $252 12 payments
  7. Pfizer Inc. $198 11 payments
  8. Abbott Laboratories $179 9 payments
  9. Nestle HealthCare Nutrition Inc. $166 10 payments
  10. Janssen Pharmaceuticals, Inc $162 12 payments
  11. Other $1,580 88 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,887 432 payments
  2. Education $50 2 payments
Products named General payments · program years 2021–2025
  1. FARXIGA $1,467 40 payments
  2. BREZTRI $944 12 payments
  3. UBRELVY $901 52 payments
  4. AIRSUPRA $747 19 payments
  5. MOUNJARO $675 42 payments
  6. TRULICITY $488 27 payments
  7. VRAYLAR $395 26 payments
  8. JARDIANCE $387 26 payments
  9. QULIPTA $323 22 payments
  10. TRELEGY ELLIPTA $308 21 payments
  11. Other $4,425 266 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 115 drugs

Part D claims

5,575

Median for Physician Assistant: 241

Drug cost

$511,495

Median for Physician Assistant: $4,110

Branded share of claims

21.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 81 $93,493
Mounjaro Tirzepatide Brand 63 $67,774
Eliquis Apixaban Brand 84 $56,796
Farxiga Dapagliflozin Propanediol Brand 44 $55,852
Trulicity Dulaglutide Brand 25 $39,566
Jardiance Empagliflozin Brand 41 $37,634
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 27 $26,987
Gemtesa Vibegron Brand 19 $14,691
Myrbetriq Mirabegron Brand 12 $12,625
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 17 $11,002

The 10 drugs with the highest cost, of 115 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$25,671

Of which drugs: $205

Medicare patients

179

Average age 73

Services billed

1,067

98 women, 81 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 46%
Diabetes 38%
Chronic kidney disease 24%
Ischemic heart disease 20%
Atrial fibrillation 20%
Depression 19%
COPD 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 13 28 $148
Injection, ceftriaxone sodium, per 250 mg J0696 Office 13 28 $9

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $254
$254 44 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $183
$183 — —
MOUNJARO
  • Lilly USA, LLC $148
$148 63 —
VRAYLAR
  • AbbVie, Inc. $117
$117 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $112
$112 17 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

434 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record